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Background: The objective of this population-based study was to assess patient, physician and tumour determinants
associated with positive surgical margins after prostatectomy, and to assess the effects of positive surgical margins
on prostate cancer-specific survival.
Methods: We included 1’254 prostate cancer patients recorded at the Geneva Cancer Registry who had radical
prostatectomy during 1990–2008. To assess factors associated with positive margins, we used logistic regression. We
assessed the effects of positive margins on prostate cancer-specific survival by Cox proportional hazard models
accounting for numerous other prognostics factors including prostate and tumour volume, the total percentage of
tumour, radiotherapy, surgical approach and surgeon’s caseload.
Results: Among men undergoing prostatectomy, 479 (38%) had positive margins. In the multivariate logistic regression
analysis, period, clinical- and pathological T stage, Prostate Specific Antigen (PSA) level, Gleason score and percentage of
tumour in the prostate were significantly associated to positive margins. Ten-year prostate cancer-specific survival was
96.6% for the negative margins group and 92.0% for the positive margins group (log rank p = 0.008). In the Cox survival
analysis adjusted for tumour characteristics, surgical margin status per se was not an independent prognostic factor while
age, pathological T, PSA level and Gleason score remained associated with prostate cancer-specific survival.
Conclusions: More aggressive tumour characteristics were strong determinants for positive margins. Furthermore,
surgical margin status per se was not an independent prognostic factor for prostate cancer-specific survival after adjusting
by the gravity of the disease in the multivariate analysis.
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Prostate cancer is the second most frequently diagnosed
cancer and the fifth most common fatal cancer among
men worldwide, the fourth for developed countries [1]. A
high percentage of men are diagnosed with early stage dis-
ease due to the spontaneous generalization of prostate
specific antigen (PSA) screening [2]. Radical prostatec-
tomy is the main treatment option for clinically localized
prostate cancer, as shown by the randomized Scandi-
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unless otherwise stated.[3]. However, as shown recently by Wilt et al., the differ-
ence between radical prostatectomy and watchful waiting
was not significant [4]. Positive surgical margins (PSMs),
identified as the presence of cancer at the inked resection
margin of the prostatectomy specimen, are a relatively
frequent finding after prostatectomy and reported in many
articles with proportions ranging from 10 to 40% [5].
Although there are many reports and studies available,
questions remain regarding determinants and effects of
PSM. Furthermore, in relation to survival, surgical margins
are the only factor which could be influenced by the
surgeon, contrary to tumour characteristics.
Some investigations have correlated patient, clinical and
histo-pathological findings with surgical margin statusd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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several determinants of surgical margins, such as type of
surgery, location of PSM, prostate weight and tumour
volume [6]; Williams et al., investigated determinants
such as period of surgery, geographical region, type of
surgery and surgeon caseload [7]; and finally Vesey et al.,
studied surgeon caseload and prostate weight [8]. They all
found that the tumour characteristics such as clinical
stage, pathological stage, Gleason score and the percent-
age of tumour in the prostate were more often signifi-
cantly associated with surgical margin status.
Furthermore, several studies have investigated the
association between surgical margins and outcome after
radical prostatectomy [9-17]. Two types of outcomes are
usually described in this context; either PSA biochemical
recurrence (BCR) through routine serum PSA monitor-
ing every six months after treatment, and/or prostate
cancer-specific survival (PCSS). PSM after radical prosta-
tectomy is known to be an independent risk factor for
BCR; however, there is no wide consensus on its impact
on survival [14-16]. Although most studies reporting on
BCR show significant association with PSM [9-12], stud-
ies reporting on PCSS show mostly non-significant asso-
ciation with PSM [13-17].
The aim of the present study was twofold; 1) to assess
patient, physician and tumour characteristics associated
with PSM after prostatectomy, and 2) to assess if PSM is




We included 1’254 patients diagnosed with prostate can-
cer between 1990 and 2008 who underwent radical pros-
tatectomy using data from the Geneva Cancer Registry in
Switzerland.
Variables
The Geneva Cancer Registry records all incident cancers
occurring in the population of the canton (approximately
475’000 inhabitants in 2009). All hospitals, pathology
laboratories, and practitioners are requested to report all
cancer patients. Trained registrars systematically abstract
data from medical and laboratory records. Physicians
regularly receive questionnaires to obtain missing data.
Recorded data include various information on patient
and tumour characteristics, treatment and outcome. The
Registry regularly assesses survival data. Active follow-up
is performed yearly using the files of the Cantonal
Population Office which is in charge of registration of the
resident population. The registrars establish cause of
death by systematically consulting clinical records and
interpreting questionnaires completed by the patient’s
physician. In general, the Registry records data ontreatments given during the first six months, however for
this study we re-opened all files and collected all treat-
ment data. The patients were followed for vital status up
to 31rst December 2011.
As variables of interest, we considered age in continu-
ous or categorical (<60, 60–69, ≥70 years), period at diag-
nosis (1990–4, 1995–9, 2000–4, 2005–8), socioeconomic
status based on last patient’s occupation (high, middle,
low, unknown), sector of care (private, public), method
of detection (screening by PSA, symptoms, other), and
surgeon caseload (the mean of prostate cancer surgeries
that the surgeons performed). For surgical approach we
considered “open” procedures (perineal and retropubic),
laparoscopic and robot assisted laparoscopic surgeries.
Because before 1998 laparoscopic and robot assisted
prostatectomies were not performed in Geneva, we
classified the “unknown” procedures before 1998 as
“open” surgical procedures. Adjuvant radiotherapy was
given in adjunction (within one year) to prostatectomy,
without signs of PSA raise. Salvage radiotherapy was
given only after PSA raise or other signs of local recur-
rence. In the analyses, the variable radiotherapy includes
both those patients with adjuvant radiotherapy and those
with salvage radiotherapy. In case radiotherapy was
accompanied by hormonal therapy, this was included in
the radiotherapy category.
All specimens were analysed by one of the three path-
ology laboratories existing in Geneva; one public and two
private. The presence of tumour cells at the inked margin
of the resection was considered to represent a PSM. A
“close” surgical margin was considered as tumour cells in
close proximity to the ink (within 1 mm from the inked
margin), according to Chuang and Epstein [18]. Besides
the surgical margin status, other tumour characteristics
were considered such as clinical stage (cT0-cT1, cT2,
cT3, cTx (unknown) and pathological stage (pT1-2, pT3-
T4) [19], PSA value at diagnosis (<10 ng/ml, 10–20, >20),
Gleason score (Gleason < 7, Gleason = 7, Gleason > 7),
margin extension as focal (unifocal and < = 3 mm) and
extensive (plurifocal and >4 mm), and tumour percentage
in the prostate. The volume of the prostate and of the
tumour were measured by multiplying the largest height,
width and length by 0.524 (H × W × L × π/6), according
to Bates et al. [20] Tumour percentage of the prostate
was calculated as tumour volume divided by the prostate
volume. As capsular extension was highly correlated with
pathological T status (intracapsular = pT1-2, extracapsu-
lar extension = pT3-4), we did not include this variable in
our analysis.
Statistical analysis
We performed a case–control study, considering patients
with PSM as cases and patients with negative surgical
margins as controls. We used the χ2 test and univariate
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ship between surgical margins and other variables. Ten-
year prostate cancer survival curves according to surgical
margins status were estimated by means of Kaplan Meyer
methods, and survival differences were tested through log
rank test. We used Cox proportional regression analyses
to assess the independent effect of surgical margins on
ten-year prostate cancer-specific survival after radical
prostatectomy while adjusting for other prognostic factors
as assessed in univariate analysis. In the logistic and Cox
regressions we regrouped negative-and close surgical
margins together for further analyses as suggested in the
literature [21]. The statistical significance level was set at p
value < 0.05. Stepwise backward elimination was used to
reduce the model to factors with p < 0.10. Statistical ana-
lysis was performed using the software Statistical Package
for Social Sciences (SPSS version 15.0, Chicago, IL).
All data analysis was conducted at the Geneva Cancer
registry. As a cancer registry we do not require Ethical per-
mission and accordingly no informed consent is required
for registry-based studies involving no contact with the
study subjects. The Registry has a general authorization,
provided by the Federal Expert Commission in charge of
data protection, to collect nominative data for research
purposes on cancer in the general population.
Results
Association between patient and tumour characteristics
and post-operative surgical margins
Among the 1’254 prostate cancer patients undergoing
prostatectomy, 479 (38.2%) had PSM, 629 (50.2%) nega-
tive surgical margins and 146 (11.6%) close surgical mar-
gins. We observed that the most common location of
PSM was at the apex (53.9%) and the posterior (19.0%) of
the prostate (data not shown).
Table 1 presents the distribution of patient characteris-
tics, tumour characteristics, and treatment according to
surgical margins and the Odds Ratios (ORs) derived from
the univariate logistic regression. The patients with nega-
tive and close margins were considered together in the
category negative margins. The mean age at diagnosis was
63 years (Standard deviation [SD] ±6.3 years) and did not
differ between the two groups of surgical margins. The
PSM rate decreased over time, from 50% in 1990–1994 to
31% in 2005–2008 (test for trend p < 0.001). Most patients
were treated in the private sector (64.1%). The majority of
the patients were diagnosed through screening (83.4%).
Close surgical margins were more often reported by the
private pathology laboratories compared to the public
ones (71.9% and 28.1% respectively, p = 0.049). The infor-
mation about lymph node dissection was available only
since 1999. Among the 1023 patients for whom we had
the information, 374 (37%) had a lymph node dissection,
and of these 347 were free of metastasis (214 in thenegative and 133 in the positive margin group). In terms
of PSM rates were higher after the open surgical proce-
dures (196/427, 45.7%) compared to robot-assisted prosta-
tectomies (35/109, 32.1%) (p = 0.010). Among the 479
patients with PSM, 32 (7%) received adjuvant radiother-
apy, and 124 (26%) received salvage radiotherapy. For the
patients with negative surgical margins, adjuvant radio-
therapy was given to only 3 of 775 (0.4%) patients, and 30
(4%) received salvage therapy. In the univariate analysis,
all tumour characteristics such as clinical and pathological
T-status, PSA level, Gleason score, prostate volume,
tumour volume and percentage were significantly associ-
ated with PSM.
Table 2 presents the results from the multi-adjusted lo-
gistic regression model. All factors significantly associated
with PSM in the univariate analysis were simultaneously
entered in the model. Clinical and pathological T status
were entered into two separate models, due to their high
co-linearity, the results presented derive from the model
with clinical T status. The following factors remained
significantly associated with PSM: period of diagnosis,
clinical T3 status compared to the cT0-1 reference cat-
egory (Odds Ratio (OR) 1.73, 95% Confidence Interval
(CI) 1.05-2.85; p = 0.031), pathological T3-4 status com-
pared to the reference category pT0-2 (OR 2.68; 95% CI
2.00-3.59; p < 0.001), PSA level 10–20 and >20 compared
to the reference category <10 (OR 1.52, 95% 1.06-2.17;
p = 0.023, and OR 1.80, 95% 1.06-3.05; p = 0.029, respect-
ively), Gleason score 7 and 8–10 compared to the refer-
ence category 2–6 (OR 1.61, 95% 1.23-2.12; p = 0.001 and
OR 2.25, 95% 1.39-3.63; p = 0.001, respectively), and
tumour percentage ≥10% compared to the reference cat-
egory of <10% (OR 2.90; 95% CI 2.21-3.81; p < 0.001).
Association between post-operative surgical margins and
prostate cancer-specific survival
During the follow-up period, 141 of the 1,254 men died
(11%) including 51 (4%) from prostate cancer. Patients
lost to follow-up were 153/1,254 (12.2%). The mean
follow-up time was 6.9 years and the median time was
6.1 years (range two months-20 years). Ten-year PCSS
was 96.6% (95% CI: 94.3-98.8) for the negative surgical
group, and 92.0% (95% CI: 88.5-95.4) for the PSM group
(log rank p = 0.008) (Figure 1). Within the negative group
the 10-year survival of patients with a truly negative mar-
gin was 97.1% (95% CI: 94.6-99.5) and that of patients
with close margins was 94.5% (95% CI: 88.8-99.9). In the
univariate Cox analysis, surgical margin status, age, sur-
geon caseload, pathological T-stage, PSA level, Gleason
score and tumour percentage were significantly associ-
ated with prostate cancer-specific survival (Table 3). In
the multivariate Cox regression including the entire set
of variables tested in crude analysis and using stepwise
backward elimination, age, pathological T-status, PSA
Table 1 Comparisona of sociodemographic, treatment and surgeon characteristics among prostate cancer patients
after prostatectomy (n = 1’254) according to surgical margin status




N % N % N (95% CI)
Age Mean (SD) 63.39 (6.00) 62.94 (6.48) 63.12 (6.30) 0.218
(t-test)
Age class
<60 127 37.1 215 62.9 342 1 0.831
60-69 276 38.3 445 61.7 721 1.05 (0.81-1.37)
≥70 76 39.8 115 60.2 191 1.12 (0.78-1.61)
Period
1990-1994 29 50.0 29 50.0 58 1 <0.001
1995-1999 105 42.9 140 57.1 245 0.75 (0.42-1.33)
2000-2004 201 40.8 292 59.2 493 0.69 (0.40-1.19)
2005-2008 144 31.4 314 68.6 458 0.46** (0.26-0.80)
Social class status
High 156 35.9 279 64.1 435 1 0.602
Middle 206 38.8 325 61.2 531 1.13 (0.87-1.47)
Low 107 40.8 155 59.2 262 1.24 (0.90-1.69)
Unknown 10 38.5 16 61.5 26 1.12 (0.50-2.52)
Sector of care
Private 312 38.8 492 61.2 804 1 0.554
Public 167 37.1 283 62.9 450 0.93 (0.73-1.18)
Method of detection
Screening 394 37.7 652 62.3 1046 1 0.434
Symptoms 43 44.3 54 55.7 97 1.32 (0.87-2.01)
Other 42 37.8 69 62.2 111 1.01 (0.67-1.51)
Type of surgery
Perineal/Retropubic 196 45.9 231 54.1 427 1 <0.001
Laparoscopic 62 39.2 96 60.8 158 0.76 (0.53-1.10)
Robot-assisted 35 32.1 74 67.9 109 0.56* (0.36-0.87)
Unknown 186 33.2 374 66.8 560 0.59*** (0.45-0.76)
Surgeon caseload (number of prostatectomies)
High (>50) 379 37.6 628 62.4 1007 1 0.235
Middle (15–50) 74 44.6 92 55.4 166 1.33 (0.96-1.86)
Low (<15) 24 32.0 51 68.0 75 0.78 (0.47-1.29)
Unknown 2 33.3 4 66.7 6 0.83 (0.15-4.55)
Radiotherapy with or without hormonal therapyc
No 325 30.5 742 69.5 1067 1 <0.001
Yes 154 82.4 33 17.6 187 10.65 (7.16-15.86)
Clinical T
cT0-cT1 83 31.8 178 68.2 261 1 <0.001
cT2 163 35.7 293 64.3 456 1.19 (0.86-1.65)
Retèl et al. BMC Urology 2014, 14:86 Page 4 of 11
http://www.biomedcentral.com/1471-2490/14/86
Table 1 Comparisona of sociodemographic, treatment and surgeon characteristics among prostate cancer patients
after prostatectomy (n = 1’254) according to surgical margin status (Continued)
cT3 79 63.2 46 36.8 125 3.68*** (2.36-5.76)
cTx 154 37.4 258 62.6 412 1.28 (0.92-1.78)
Pathological T
pT0-pT2 239 27.5 629 72.5 868 1 <0.001
pT3-pT4 240 62.2 146 37.8 386 4.33 (3.36-5.58)
PSA level
0-9 217 32.8 445 67.2 662 1 <0.001
10-20 98 51.0 94 49.0 192 2.14*** (1.54-2.96)
21+ 57 64.0 32 36.0 89 3.65*** (2.30-5.80)
Unknown 107 34.4 204 65.6 311 1.08 (0.81-1.43)
Gleason
2-6 218 30.5 497 69.5 715 1 <0.001
7 195 45.2 236 54.8 431 1.88*** (1.47-2.41)
8-10 60 61.9 37 38.1 97 3.70*** (2.37-5.74)
Unknown 6 54.5 5 45.5 11 2.74 (0.83-9.06)
Prostate volume (cm3)
≤60 422 41.0 607 59.0 1029 1 <0.001
>60 53 25.7 153 74.3 206 0.50*** (0.36-0.70)
Unknown 4 21.1 15 78.9 19 0.38 (0.13-1.16)
Tumour volume (cm3)
≤10 347 35.7 624 64.3 971 1 <0.001
>10 58 70.7 24 29.3 82 4.35*** (2.65-7.12)
Unknown 74 36.8 127 63.2 201 1.05 (0.76-1.44)
Tumour percentaged
≤10% 202 26.7 554 73.3 756 1 <0.001
>10% 252 57.9 183 42.1 435 3.78*** (2.94-4.85)
Unknown 25 39.7 38 60.3 63 1.80* (1.06-3.07)
Total 479 38.2 775 61.8 1245
Geneva Cancer Registry 1990–2008.
aCrude logistic regression comparing patients with positive surgical margins (the cases) with those with negative surgical margins (the controls).
bNegative and close.
cRadiotherapy includes both salvage and adjuvant categories.
dTumour percentage of the prostate was calculated as tumour volume divided by the prostate volume
CI: confidence interval.
*p < 0.05; **p < 0.01; ***p < 0.001.
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with PCSS (Table 3). Men in the age category 60–69 (HR
0.28; 95% CI 0.11-0.66; p = 0.004) had a lower risk of
mortality compared to the reference category of
<60 years. Men with a pathological T3-4 status had a
higher risk of mortality compared to the reference cat-
egory pT0-2 (HR 2.61; 95% CI 1.05-6.48; p = 0.039), as
well as men with PSA level greater than 21 (HR 2.89;
95% CI 1.18-7.08; p = 0.020) and a Gleason score 7 (HR
5.28; 95% CI 1.67-16.7; p = 0.005), 8–10 (HR 22.53; 95%
CI 7.10-71.5; p < 0.001) and an unknown Gleason score
(HR 10.59; 95% CI 1.04-108; p = 0.046) had a higher risk
of mortality compared to the reference category 2–6. Yet,surgical margin status was not any longer significantly as-
sociated with prostate cancer-specific mortality.
Discussion
In the current study, we found that more aggressive
tumour characteristics are responsible for both PSM
after prostatectomy and worse prostate cancer-specific
survival. Although, surgical margin status was associated
with prostate cancer-specific survival in univariate ana-
lysis with PSM patients showing a doubled risk of dying
as compared to NSM patients, this increased risk disap-
peared after adjusting for variables related to the gravity
of the disease in the multivariate analysis. Yossepowitch
Table 2 Multiadjusted comparisona of sociodemographic, treatment and surgeon characteristics among prostate
cancer patients after prostatectomy (n = 1’254) according to surgical margin status




N % N % (95% CI)
Period
1990-1994 29 50.0 29 50.0 1 0.025
1995-1999 105 42.9 140 57.1 1.05 (0.53-2.06)
2000-2004 201 40.8 292 59.2 1.47 (0.73-2.99)
2005-2008 144 31.4 314 68.6 0.92 (0.44-1.92)
Type of surgery
Perineal/Retropubic 196 45.9 231 54.1 1 0.443
Laparoscopic 62 39.2 96 60.8 0.96 (0.61-1.53)
Robot-assisted 35 32.1 74 67.9 0.96 (0.55-1.69)
Unknown 186 33.2 374 66.8 0.77 (0.52-1.12)
Clinical T
cT0-cT1 83 31.8 178 68.2 1 0.038
cT2 163 35.7 293 64.3 0.93 (0.65-1.31)
cT3 79 63.2 46 36.8 1.73* (1.05-2.85)
cTx 154 37.4 258 62.6 1.18 (0.82-1.70)
Pathological T
pT0-pT2 239 27.5 629 72.5 1 <0.001
pT3-pT4 240 62.2 146 37.8 2.68 (2.00-3.59)
PSA level
0-9 217 32.8 445 67.2 1 0.036
10-20 98 51.0 94 49.0 1.52* (1.06-2.17)
21+ 57 64.0 32 36.0 1.80* (1.06-3.05)
Unknown 107 34.4 204 65.6 1.03 (0.74-1.42)
Gleason
2-6 218 30.5 497 69.5 1 <0.001
7 195 45.2 236 54.8 1.61*** (1.23-2.12)
8-10 60 61.9 37 38.1 2.25*** (1.39-3.63)
Unknown 6 54.5 5 45.5 1.87 (0.46-7.71)
Tumour percentagec
≤10% 202 26.7 554 73.3 1 <0.001
>10% 252 57.9 183 42.1 2.90*** (2.21-3.81)
Unknown 25 39.7 38 60.3 1.37 (0.78-2.43)
Total 479 38.2 775 61.8
Geneva Cancer Registry 1990–2008.
aLogistic regression adjusted for all variables (clinical and pathological T status were entered separately, due to their co-linearity; the results presented derive from
the model with clinical T).
bNegative and close.
cTumour percentage of the prostate was calculated as tumour volume divided by the prostate volume.
CI: confidence interval.
*p < 0.05; ***p < 0.001.
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Figure 1 Kaplan Meier curve of the prostate cancer-specific survival among prostate cancer patients after radical prostatectomy
according to surgical margin, Geneva Cancer Registry, 1990–2010. No. at risk: Numbers of persons at risk at the beginning of the period of
follow-up. NSM: Negative Surgical Margin. PSM: Positive Surgical Margin.
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literature covering the last ten years, on positive surgical
margins after radical prostatectomy evaluating also their
oncologic impacts [22]. The authors concluded that the
long term impact of positive margins on cancer progres-
sion and specific survival is highly variable and largely
dependent on additional risk modifiers. In fact, they noted
that while all the revised studies showed a significant asso-
ciation between positive margins and biochemical recur-
rence, the data pertaining to metastatic progression and
death were less consistent with only two studies indicating
that PSMs were significantly associated with an increased
risk of prostate cancer-specific mortality [15,23]. In the
Surveillance, Epidemiology and End Results (SEER) data
analysis, Wright et al., found a 2.6-fold increased un-
adjusted risk of prostate cancer-specific mortality that
remained significant also after adjusting for grade, stage,
additional radiotherapy, age, race, registry and year of
diagnosis. However, when stratified by adverse patho-
logical features of the tumour these findings held only for
those with higher grade or pT3 tumours [15]. In a more
recent study on a single surgeon cohort, Chalfin et al.,
showed that PSM had a statistically significant, but mod-
est, adverse effect on prostate cancer-specific mortality ina model including Gleason score, year of surgery and
pathological stage [23]. Similarly to these studies, in our
study we found a strong association of prostate cancer-
specific mortality with PSM in univariate analysis, how-
ever, this association disappeared in the multivariate
analysis. Unlike these studies in our multivariate model
we simultaneously adjusted for all the pathological
adverse tumour features, including Gleason, stage, PSA
level, percent of the tumour in the prostate, which
emerged as the strongest predictors of mortality. Consist-
ently with the results of another recent study, our results
suggest that PSM alone does not increase the risk of
dying from prostate cancer [24].
In the literature, surgical margins after prostatectomy
are evaluated in different ways through different study
designs. Population based studies are valuable designs
mostly because of the large cohorts involved, however
the accuracy is often not very high. After a systematic
audit of the SEER registry, Shah et al., showed that 30%
of radical prostatectomies performed in 2007 were in-
accurately coded, and concluded that clinicians and
investigators should recognize the limitations of tumour
registry data on PSM [25]. For the current study, we
opened all the files and re-checked all parameters and
Table 3 Prognostics factors of 10 years prostate cancer mortality derived from Cox regression analysis among prostate
cancer patients with prostatectomy
Total PC specific death Unadjusted hazard ratio Adjusted hazard ratioa
N N % HR (95% CI) p-value HR (95% CI) p-value
Surgical Margin
Negativeb 775 12 1.6 1 0.010
Positive 479 21 4.4 2.54* (1.25-5.16)
Age class
<60 342 12 3.5 1 0.004 1 0.001
60-69 721 10 1.4 0.39* (0.17-0.91) 0.28** (0.11-0.66)
≥70 191 11 5.8 1.68 (0.74-3.81) 1.31 (0.56-3.02)
Period
1990-99 303 17 5.6 1 0.156
2000-08 951 16 1.7 0.60 (0.29-1.22)
Method of detection
Screening 1046 23 2.2 1.00 0.109
Symptoms 97 8 8.3 2.34* (1.04-5.28)
Other 111 2 1.8 0.89 (0.21-3.76)
Surgeon caseload
High (>50) 1007 18 1.8 1 0.006
Middle (15–50) 166 12 7.2 3.68*** (1.78-7.63)
Low (<15) 75 3 4.0 2.31 (0.68-7.84)
Unknown 6 0 0.0 -
Clinical T
cT0-cT1 261 2 0.8 1 0.359
cT2 456 13 2.9 2.92 (0.66-13.0)
cT3 125 6 4.8 4.33 (0.87-21.5)
cTx 412 12 2.9 3.06 (0.69-13.7)
Pathological T
pT0-pT2 868 7 0.8 1 <0.001 1 0.0387
pT3-pT4 386 26 6.7 6.97*** (3.02-16.1) 2.61* (1.05-6.48)
PSA level
0-9 662 10 1.5 1 <0.001 1 0.0379
10-20 192 7 3.7 1.71 (0.65-4.52) 1.02 (0.38-2.76)
21+ 89 12 13.5 6.40*** (2.75-14.9) 2.89* (1.18-7.08)
Unknown 311 4 1.3 0.63 (0.20-2.01) 0.76 (0.23-2.46)
Gleason
2-6 715 4 0.6 1 <0.001 1 <0.001
7 431 12 2. 8 6.59** (2.12-20.5) 5.28** (1.67-16.7)
8-10 97 16 16.5 37.8*** (12.6-113) 22.53*** (7.10-71.5)
Unknown 11 1 9.1 12.6* (1.40-113) 10.59* (1.04-107)
Tumour percentagec
<10% 756 6 0.8 1 <0.001
≥10% 435 24 5.5 5.88*** (2.40-14.4)
Unknown 63 3 4.8 4.46* (1.11-17.9)
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Table 3 Prognostics factors of 10 years prostate cancer mortality derived from Cox regression analysis among prostate
cancer patients with prostatectomy (Continued)
Radiotherapyd
No 1067 23 2.2 1 0.038
Yes 187 10 5.4 2.19* (1.04-4.61)
Total 1254 33 2.63
Geneva Cancer Registry 1990–2008.
aAdjusted HRs were calculated using Cox Backward Regression including the entire set of variables tested in crude analysis, except clinical T.
bNegative and close.
cRadiotherapy includes both salvage and adjuvant categories.
dTumour percentage of the prostate was calculated as tumour volume divided by the prostate volume.
CI: Confidence interval.
PC: Prostate Cancer.
*p < 0.05; **p < 0.01; ***p < 0.001.
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to the available literature based on cancer registries.
This could explain why the overall proportion of 38.2%
PSM is higher, compared to the range found in other
studies [5]. The proportion of PSM decreased during
the study period, from 50% in 1990–1994, to 31% in
2005–2008. Stage shift and surgeons at the end of the
learning curve of prostatectomy, may explain the find-
ing of significantly lower PSM rates in the later prosta-
tectomies. In fact, we found that the ratio of cancer with
pathological T0-T2/T3-T4 went from 0.7 in 1990–1994,
to 3.4 in 2005–2008 (test for trend = 54.58, p < 0.001).
On the other hand, we also observed in the univariate
analysis that “closed” surgeries such as laparoscopic and
robot-assisted surgeries yielded significantly less PSM,
confirming the findings of Touijer et al. [26] However,
for the cases treated in the private sector, the surgical
procedure was not always reported. Also, most robot-
assisted surgeries reported in our study were performed
in the public hospital by a selected group of surgeons.
The number of deaths from prostate cancer in the groups
of surgery procedures was too low to allow showing an
association with survival.
The present study was a retrospective analysis with a
relative short follow-up, which is the main limitation of
the study. This could be the main reason for the absence
of impact of PSM on PCSS. If we accept that BCR is a sur-
rogate of PCSS, since the influence of PSM on BCR is well
established, we could foresee that only a study with a
median time of follow-up > 10 years would be able to
highlight PSM as a significant predictor of PCSS on a
multivariate basis. However, we could not provide data re-
garding biochemical recurrences, as the Geneva Cancer
Registry does not collect this information. Furthermore,
the number of prostate cancer deaths was very low (n = 33
at 10 year and n = 51 at the end of follow-up), another
possible reason for underpowered results. However, we
observed similar survival rates in other studies [14,15].
Another limitation is the use of different pathology labora-
tories (private and public) in the area. This could havecaused inter-observer variability, which was evident in the
classification of close surgical margins: 72% were reported
from the private pathology laboratory and 28% from the
public laboratory. Because of the limited number of pa-
tients with close surgical margins, those patients were
regrouped together with the negative surgical margins in
further analyses, as already suggested in the literature [21].
Another limitation of the study is the relatively high
percentage of patients lost to follow-up (12.2%). This is
peculiar to the Geneva canton, related to the fact that
Geneva is an international city, with 43% of the population
consisting of foreigners and a strong work-related migra-
tion rate. We compared the patients lost to follow-up to
the rest of the study population and found no significant
differences in terms of patient, tumour and treatment
characteristics. Therefore, we find it unlikely that this
selection could have strongly biased our results in terms
of the impact of PSM on mortality. On the other hand,
because 12% of the cohort was not at risk of prostate can-
cer mortality, the substantial number of patients who were
lost to follow-up could be one of the reasons for the high
specific survival rate that we observed. As we had only
partial information on the presence of comorbidities, this
variable was not included in our analysis. However, in this
population comorbidities are expected to have had only a
limited impact on survival as the population is younger
and therefore healthier; among the 231 study patients for
whom information on comorbidities was available, only
32% reported at least one comorbidity, as opposed to 51%
of all prostate cancer patients aged >65 years in our regis-
try. Another variable we did not include in the analyses, as
available only since 2008, was the information about
nerve-sparing approach, however, previous studies have
shown that nerve-sparing procedures are safe and not
associated with an increased positive margin rate nor on
disease progression [27]. The strength of our study is that
the population-based approach permits both to generalize
the results to the whole population and to examine the
effect of PSM in routine care. In addition, the re-opening
of all the patients’ files gave further strength to this study,
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data. If we consider the context of data collection in a can-
cer registry, one could generally recommend, as recently
stated by Raldow et al., that the extension of the treatment
registration period from six to nine months or even one
year, especially in the case of prostate cancer treatment,
could be an advantage for future studies like this one [28].
Finally, in our analyses we could take into account of a
large number of important prognostic factors for prostate
cancer mortality.
Although the association between PSM and survival is
not clear, the link with biochemical recurrence is well estab-
lished [9-12]. Indeed, in the 2011 European Association of
Urology guidelines, as well as the National Comprehensive
Cancer Network (NCCN) guidelines, it has been recom-
mended to take into account surgical margin status in the
adjuvant treatment decision, as an independent risk factor
for BCR [29,30]. In a recent publication, Lu et al., found
that close surgical margins as well were independently asso-
ciated with a twofold risk of postoperative biochemical
recurrence and suggest that close margins might be an indi-
cator of local recurrence, and therefore also be of relevance
when considering salvage therapy [31]. To date only the
SWOG 8794 trial with its long median follow-up could
demonstrate improved overall survival with adjuvant radi-
ation therapy in men with pT3a and/or positive margin dis-
ease in exploratory analysis. However, the differential effect
of adjuvant radiotherapy vs early salvage radiotherapy was
not evaluated in this trial, as salvage at PSA recurrence was
not mandated by protocol in the observation arm ([32]). In
a situation where the scientific evidence in favour of early
vs. delayed use of radiotherapy to control local recurrence
is still lacking, it seems reasonable to add the information
on PSM to the other clinical prognostic variables in order
to obtain a more comprehensive assessment of the individ-
ual risk [22].Conclusions
To conclude, our data showed that surgical margins after
prostatectomy are predominantly predicted by tumour
characteristics, but are not independently associated with
prostate cancer-specific survival. Aggressive tumour char-
acteristics are correlated with both positive surgical
margins after prostatectomy and worse prostate cancer-
specific survival. These results should be considered for
future research and when evaluating patients with a PSM
for adjuvant and/or salvage therapy.Abbreviations
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